



XIII. DNY DIAGNOSTICKÉ, PREDIKTIVNÍ A EXPERIMENTÁLNÍ ONKOLOGIE / XIII. DIAGNOSTIC, PREDICTIVE AND EXPERIMENTAL ONCOLOGY DAYS

ÚTERÝ / TUESDAY - 28. listopadu 2017 / November 28th, 2017

12:30 - 12:45 WELCOME & INTRODUCTION

Cancer therapeutics I.

Chairs: Petr Dzubak, Marian Hajduch

12:45 - 13:30	5-ene-thiazolidinone based design of drug-like molecule Roman Lesyk	es	
13:30 - 14:00	Challenges and best-practices in academic cancer drug <i>Marian Hajduch</i>	g development	
14:00 - 14:15	Semisynthetic triterpenoid heterocycles - synthesis, cyt action	otoxicity, and studies of t	their mechanism of
	Milan Urban		
14:15 - 14:30	Design of HTS libraries using novel 3D pharmacophore <i>Pavlo Polishchuk</i>	signatures	
14:30 - 14:45	Fluoroquinolones as perspective anti-cancer drugs		
	Natalie Taborska	△ MedChemBio	
14:45 - 15:15	COFFEE BREAK	klastr medicinální chemie a chemické biologie	Olomoucký kraj

Cancer therapeutics II.

Chairs: Milos Petrik, Milan Urban

15:15 - 15:45	Phytohormones cytokinin ribosides as anticancer agents Jiri Voller
15:45 - 16:00	99mTc-labelled hydroxyapatite nanoparticles and their in vitro / in vivo characterisation
	Zbynek Novy
16:00 - 16:15	Repurposing of anti-cancer drugs as potential inhibitors of toxic Tau aggregates Narendran Annadurai
16:15 - 16:35	CRISPR-mediated gene tagging with the bioluminescent HiBiT technology
	Oleksii Ivanov
16:35 - 16:50	How we do high content/throughput screening of anti-cancer molecules Pawel Znojek
16:50 - 17:05	Proteomic profiling reveals DNA damage, nucleolar and ribosomal stress are the main responses to oxaliplatin treatment in cancer cells
	Tomas Ozdian

STŘEDA / WEDNESDAY - 29. listopadu 2017 / November 29th, 2017

Translational cancer research I.

Chairs: Ondrej Slaby, Jiri Drabek

9:00 - 9:45	Unconventional transcripts, fusion genes and neocentromeres: the hidden face of genomic amplifications in cancer.
	Clelia Tiziana Storlazzi
9:45 - 10:30	How can we target the CXCL12-CXCR4 axis in oncology patients
	Stefania Scala
10:30 - 11:00	Genomic data as the basis for personalized therapeutic planning in pediatric oncology
	Ondrej Slaby
11:00 - 11:15	COFFEE BREAK



Molecular targets & biomarkers I.

Chairs: Jiri Sana, Josef Srovnal

11:15 - 11:30	Immunotherapy prediction in cancer patients using microsatellite instability
	Josef Srovnal
11:30 - 11:45	MiRNA profiling in recurrent and non-recurrent meningeomas
	Hanus Slavik
11:45 - 12:00	Cytogenetic analysis of recurrent glioblastomas
	Magdalena Megova
12:00 - 12:15	The opioid and cannabinoid receptors expression affects survival of colorectal cancer patients
	Monika Vidlarova
12:15 - 12:30	Identification of candidate genes underlying soft tissue sarcoma progression using a progression series of murine fibrosarcoma cell lines
	Jiri Hatina
12:30 - 13:30	LUNCH AND POSTER PRESENTATION (Note: the authors are kindly requested to present posters in between 13:00-13:30)

Translational cancer research I.

Chairs: Ondrej Slaby, Jiri Drabek

13:30 - 14:15

15:45 - 16:15

19:00

	Andreas Scherer
14:15 - 14:45	Epigenetic and paracrine control of hepatic cancer stemness Manilo Vinciguerra
14:45 - 15:00	Life is never flat: The rational use of 3D cell cultures as more predictive preclinical tumor models
	Viswanath Das
15:00 - 15:15	MicroRNA analysis in cerebrospinal fluid of glioblastoma patients
	Alena Kopkova
15:15 - 15:30	Global microRNA expression analysis of Sox-2 positive and negative glioblastoma cells <i>Jiri Sana</i>
15:30 - 15:45	COFFEE BREAK

Optimized design and analysis of preclinical intervention studies in vivo

New technologies & bioinformatics

Marta Dzimkova

Strategies for molecular target identification

Chairs: Petr Dzubak, Martin Mistrik

	Petr Dzubak
16:15 - 16:30	Bioinformatic analysis of massive parallel sequencing data for cancer research Petr Vojta
16:30 - 16:45	Variants in shotgun proteomics Miro Hruska
16:45 - 17:00	Chronic lymphocytic leukemia cases with stereotyped B-cell receptors: knowledgebase, bioinformatics tools, data management and reporting towards personalised biomedical and clinical applications *Tomas Reigl*
17:00 - 17:15	A novelty role of CDK12 in regulation of DNA damage response by altering methylation of miR-152 and targeting downstream regulatory genes

CONFERENCE DINNER (NH hotel restaurant, for dinner-registered participants only)







Molecular targets & biomarkers II.

Chairs: Marian Hajduch, Jiri Drabek

9:00 - 9:45	New biomarkers – host methylation for management of women with a screen positive test Chris Meijer
9:45 - 10:00	Pitfalls in HPV68a detection Hana Jaworek
10:00 - 10:15	Molecular cytogenetics of "double/triple hit" - high-grade B-cell lymphoma: a new entity of mature B-cell neoplasms Helena Urbankova
10:15 - 10:30	Human papillomavirus infection in non-small cell lung cancer Vladimira Koudelakova
10:30 - 10:45	COFFEE BREAK

Molecular targets & biomarkers III.

Chairs: Milan Reinis, Pavel Moudry

10:45 - 11:00	Comparative analysis of senescent tumour cells induced by docetaxel or immunomodulatory cytokines <i>Milan Reinis</i>
11:00 - 11:15	Downregulation of uncharacterized human HEATR1 protein activates p53 and induces ribosomal stress Zsofia Turi
11:15 - 11:30	Prostate cancer cell lines and patient-derived tissues as a model for therapy decision on inhibition of PARP1 or HDAC in combination with gamma irradiation Dusana Majera
11:30 - 11: 45	Prognostic and predictive value of loss of nuclear RAD51 immunoreactivity in resected non-small cell lung cancer patients *Marjam Gachechiladze**
11:45 - 12:00	CLOSING CEREMONY
12:00	LUNCH
12.00	LUITOIT



Postery / Posters

1 Steps for improving reproducibility in biomedical research

Jiri Drabek

2 Automatic cytogenetic system Metafer®: optimization and comparison with manual method

Oliver Pesat

- 3 Gene aberrations in IDH-wild type glioblastoma
 Zuzana Sporikova
- 4 OncoScan analysis of good and bad responders to bevacizumab among mCRC patients

Karolina Bartakova

5 Investigation of biocompatibility and cytotoxic effects of TiO₂ nanoparticles with organic surface modifications

Zuzana Skubalova

6 Study on influence of surface modifications of apoferritin on intracellular delivery of ellipticine

Barbora Tesarova

7 Stability of apoferritin modified with ANTI-hNET peptides for active targeting of neuroblastoma cells

Marketa Charousova

8 Trisubstituted purine inhibitors of PDGFRα with high selectivity toward human eosinophilic cell line EOL-1

Veronika Malinkova

9 Search for new anticancer agents among 4-thiazolidinones

Danylo Kaminskyy

10 Non-invasive lung cancer diagnostics using proteomic biomarkers in exhaled breath condensate.

Jana Vaclavkova

11 Finding molecular patterns relevant for toxicity end-points

Mariia Matveieva

12 Impact of hypoxia on sensitivity of colorectal carcinoma cells towards microtubule-targeting agents

Jiri Rehulka

13 Folic acid conjugates with purine cyclindependent kinase inhibitors

Denisa Hendrychova

14 Mass spectrometry-based proteomic analysis for subtyping of amyloid deposits from FFPE and SFA

Dusan Holub

15 Cytotoxic Triterpenes and Study of their Mechanism of Action

Jiri Hodon

16 GLASS: assisted mutation detection in Sanger data

Karol Pal

- 17 Antiparasitic activity of anticancer drugs against kinetoplastid parasite Leishmania major Ermin Schadich
- 18 Pilotní studie molekulárního testování HPV infekce u nádorů z různých oblastí hlavy a krku **Kristyna Glendova**
- 19 Cytotoxicity profiling of new chemical compounds with chelating activities using high-throughput screening

Sona Gurska